<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884011</url>
  </required_header>
  <id_info>
    <org_study_id>16081001</org_study_id>
    <nct_id>NCT02884011</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock</brief_title>
  <official_title>Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective study to examine the effects of chronic antihypertensive medications on
      vasopressor dosing in septic shock
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a retrospective four-cohort study. The four cohorts will be septic shock
      patients that were: 1) not on either a chronic β-blocker or chronic
      angiotensin-converting-enzyme inhibitor (ACE-Inhibitor), 2) on chronic β-blocker, 3) on
      ACE-Inhibitor, and 4) on both chronic β-blocker and ACE-inhibitor
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total vasopressor dose</measure>
    <time_frame>48 hours</time_frame>
    <description>The primary objective is to determine the effect of chronic β-blocker or ACE-inhibitor on vasopressor dosing in the first 48 hours of septic shock. Vasopressor types and cumulative doses including: norepinephrine, epinephrine, phenylephrine, dopamine, and vasopressin. Epinephrine, phenylephrine, and dopamine will be converted to norepinephrine equivalents in concordance with other literature: 100 mcg dopamine equivalent to 1 mcg norepinephrine, 1 mcg epinephrine equivalent to 1 mcg norepinephrine, and 2.2 mcg phenylephrine equivalent to 1 mcg norepinephrine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative fluid volume</measure>
    <time_frame>48 hours</time_frame>
    <description>Cumulative fluid volume (mL). Example fluids include, 0.9% normal saline, Plasmalyte A, 0.45% normal saline + 5% dextrose, lactated ringers, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotrope use</measure>
    <time_frame>6, 12, 24, 48 hours</time_frame>
    <description>Cumulative inotrope use at different time points (total mg). Example inotropes include dobutamine and milrinone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydrocortisone use</measure>
    <time_frame>6, 12, 24, 48 hours</time_frame>
    <description>Cumulative hydrocortisone (mg) use at different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative vasopressor dose for patients receiving other antihypertensives</measure>
    <time_frame>6, 12, 24, 48 hours</time_frame>
    <description>To determine cumulative vasopressor dose at various time points of patients on chronic calcium channel blocker or other antihypertensives (i.e., hydralazine, clonidine, angiotensin-receptor-blocker (ARB), etc). Vasopressor types and cumulative doses including: norepinephrine, epinephrine, phenylephrine, dopamine, and vasopressin. Epinephrine, phenylephrine, and dopamine will be converted to norepinephrine equivalents in concordance with other literature: 100 mcg dopamine equivalent to 1 mcg norepinephrine, 1 mcg epinephrine equivalent to 1 mcg norepinephrine, and 2.2 mcg phenylephrine equivalent to 1 mcg norepinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-hour vasopressor dose</measure>
    <time_frame>6 hours</time_frame>
    <description>Vasopressor types and cumulative doses including: norepinephrine, epinephrine, phenylephrine, dopamine, and vasopressin. Epinephrine, phenylephrine, and dopamine will be converted to norepinephrine equivalents in concordance with other literature: 100 mcg dopamine equivalent to 1 mcg norepinephrine, 1 mcg epinephrine equivalent to 1 mcg norepinephrine, and 2.2 mcg phenylephrine equivalent to 1 mcg norepinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-hour vasopressor dose</measure>
    <time_frame>12 hours</time_frame>
    <description>Vasopressor types and cumulative doses including: norepinephrine, epinephrine, phenylephrine, dopamine, and vasopressin. Epinephrine, phenylephrine, and dopamine will be converted to norepinephrine equivalents in concordance with other literature: 100 mcg dopamine equivalent to 1 mcg norepinephrine, 1 mcg epinephrine equivalent to 1 mcg norepinephrine, and 2.2 mcg phenylephrine equivalent to 1 mcg norepinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour vasopressor dose</measure>
    <time_frame>24 hours</time_frame>
    <description>Vasopressor types and cumulative doses including: norepinephrine, epinephrine, phenylephrine, dopamine, and vasopressin. Epinephrine, phenylephrine, and dopamine will be converted to norepinephrine equivalents in concordance with other literature: 100 mcg dopamine equivalent to 1 mcg norepinephrine, 1 mcg epinephrine equivalent to 1 mcg norepinephrine, and 2.2 mcg phenylephrine equivalent to 1 mcg norepinephrine</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">133</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>No chronic antihypertensives</arm_group_label>
    <description>not on either a chronic β-blocker or ACE-Inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>β-blocker</arm_group_label>
    <description>on chronic β-blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-Inhibitor</arm_group_label>
    <description>on chronic ACE-Inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Both β-blocker and ACE-inhibitor</arm_group_label>
    <description>on both chronic β-blocker and ACE-inhibitor</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult, non-pregnant medical intensive care unite (MICU) patients with septic shock
        requiring vasopressor support
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 18 years of age or older

          -  Diagnosis of septic shock requiring vasopressor therapy (norepinephrine, epinephrine,
             phenylephrine, dopamine, or vasopressin)

          -  Admitted to an intensive care unit (ICU) at Rush University Medical Center (RUMC)

          -  Time frame: 01/01/2012 to 07/1/2016

        Exclusion Criteria:

          -  Pregnant patients

          -  Transfer from outside hospital on vasopressors

          -  Admitted in cardiopulmonary arrest

          -  Prior arrest within 24 hours of admission to RUMC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua DeMott, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ishaq Lat, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gourang Patel, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush Univeristy Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic antihypertensives</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Vasopressor</keyword>
  <keyword>Vasopressor dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

